Table 2.

PCT inactivates enveloped and nonenveloped viruses in plasma at high initial titers *

Viruses	Pre‐PCT titer (n = 4)	Post‐PCT titer (n = 4)	Log‐reduction†
Enveloped
HIV‐1, cell‐free	106.1±0.1 PFU/mL	<10−0.8±0.02 PFU/mL	>6.8 ± 0.1
HIV‐1, cell‐associated	105.9±0.2 PFU/mL	<10−0.5±0 PFU/mL	>6.4 ± 0.2
HTLV‐I	104.0±0.2 FFU/mL	≤10−0.5±0.8 FFU/mL	≥4.5 ± 0.7
HTLV‐II	104.7±0.1 FFU/mL	<10−1.0±0 FFU/mL	>5.7 ± 0.1
HBV‡, §	104.5 CID50/unit	None detected in 250 mL	>4.5
HCV‡, §	104.5 CID50/unit	None detected in 250 mL	>4.5
DHBV	105.6±0.2 ID50/mL	101.2‐101.3 ID50/mL	4.4‐4.5
BVDV	104.5±0.03 PFU/mL	<10−1.5±0 PFU/mL	≥6.0 ± 0.03
WNV	106.7±0.3 PFU/mL	≤10−0.1±0.2 PFU/mL	≥6.8 ± 0.5
SARS‐CoV	104.0±0.1 PFU/mL	≤10−1.5±0 PFU/mL	≥5.5 ± 0.1
Nonenveloped
Human adenovirus 5	105.5±0.5 PFU/mL	≤10−1.3±0.3 PFU/mL	≥6.8 ± 0.4
Bluetongue virus	104.0±0.2 PFU/mL	10−1.0±0.3 PFU/mL	5.1 ± 0.2

^* Results are reported as mean ± SD. n = number of replicates done for each virus; PFU/mL = plaque‐forming units per milliliter; FFU/mL = foci‐forming units per milliliter; ID₅₀ = infectious dose necessary for infection of 50 percent of inoculated ducks; CID₅₀ = infectious dose necessary for infection of 50 percent of inoculated chimpanzees.

^† Log‐reduction was calculated as the logarithm of the ratio of the pre‐PCT titer to the post‐PCT titer.

^‡ n = 3.

^§ Inactivation was done in 250 mL instead of the 600 mL as specified under Materials and Methods.